[1] Walker S.Updates in non-small cell lung cancer[J]. Clin J Oncol Nurs,2008,12(4):587-596. [2] NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials[J]. J Clin Oncol,2008,26(28):4617-4625. [3] Eisenhauer EA, Therasse P, Bogaerts J, et al.New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)[J]. Eur J Cancer,2009,45(2):228-247. [4] Bertino EM, Otterson GA.Benefits and limitations of antiangiogenic agents in patients with non-small cell lung cancer[J]. Lung Cancer,2010,70(3):233-246. [5] Lee HY, Lee KS, Ahn MJ, et al.New CT response criteria in non-small cell lung cancer: proposal and application in EGFR tyrosine kinase inhibitor therapy[J]. Lung Cancer,2011,73(1):63-69. [6] Sandler AB, Schiller JH, Gray R, et al.Retrospective evaluation of the clinical and radiographic risk factors associated with severe pulmonary hemorrhage in first-line advanced, unresectable non-small-cell lung cancer treated with Carboplatin and Paclitaxel plus bevacizumab[J]. J Clin Oncol,2009,27(9):1405-1412. [7] Johnson DH, Fehrenbacher L, Novotny WF, et al.Randomized phase Ⅱ trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer[J]. J Clin Oncol,2004,22(11):2184-2191. [8] Choi H, Charnsangavej C, Faria SC, et al.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria[J]. J Clin Oncol,2007,25(13):1753-1759. [9] Benjamin RS, Choi H, Macapinlac HA, et al.We should desist using RECIST, at least in GIST[J]. J Clin Oncol,2007,25(13):1760-1764. [10] Meyer M, Hohenberger P, Apfaltrer P, et al.CT-based response assessment of advanced gastrointestinal stromal tumor: dual energy CT provides a more predictive ima-ging biomarker of clinical benefit than RECIST or Choi criteria[J]. Eur J Radiol,2013,82(6):923-928. [11] Chandarana H, Megibow AJ, Cohen BA, et al.Iodine quantification with dual-energy CT: phantom study and preliminary experience with renal masses[J]. AJR Am J Roentgenol,2011,196(6):W693-W700. [12] Maeda H, Fang J, Inutsuka T, et al.Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications[J]. Int Immunopharmacol,2003,3(3):319-328. [13] Uhrig M, Sedlmair M, Schlemmer HP, et al.Monitoring targeted therapy using dual-energy CT: semi-automatic RECIST plus supplementary functional information by quantifying iodine uptake of melanoma metastases[J]. Cancer Imaging,2013,13(3):306-313. [14] Kawai T, Shibamoto Y, Hara M, et al.Can dual-energy CT evaluate contrast enhancement of ground-glass atte-nuation? Phantom and preliminary clinical studies[J]. Acad Radiol,2011,18(6):682-689. [15] Zhang LJ, Wu S, Wang M, et al.Quantitative dual energy CT measurements in rabbit VX2 liver tumors: Comparison to perfusion CT measurements and histopathological findings[J]. Eur J Radiol,2012,81(8):1766-1775. [16] Klauss M, Stiller W, Pahn G, et al.Dual-energy perfusion-CT of pancreatic adenocarcinoma[J]. Eur J Radiol,2013,82(2):208-214. [17] Ascenti G, Mileto A, Krauss B, et al.Distinguishing enhancing from nonenhancing renal masses with dual-source dual-energy CT: iodine quantification versus standard enhancement measurements[J]. Eur Radiol,2013,23(8):2288-2295. [18] Schmid-Bindert G, Henzler T, Chu TQ, et al.Functional imaging of lung cancer using dual energy CT: how does iodine related attenuation correlate with standardized uptake value of 18FDG-PET-CT?[J]. Eur Radiol,2012,22(1):93-103. [19] Lee SH, Hur J, Kim YJ, et al.Additional value of dual-energy CT to differentiate between benign and malignant mediastinal tumors: an initial experience[J]. Eur J Radiol,2013,82(11):2043-2049. [20] Moding EJ, Clark DP, Qi Y, et al.Dual-energy micro-computed tomography imaging of radiation-induced vascular changes in primary mouse sarcomas[J]. Int J Radiat Oncol Biol Phys,2013,85(5):1353-1359. [21] Baxa J, Vondráková A, Matou?ková T, et al. Dual-phase dual-energy CT in patients with lung cancer: assessment of the additional value of iodine quantification in lymph node therapy response[J]. Eur Radiol,2014,24(8):1981-1988. [22] Faivre S, Zappa M, Vilgrain V, et al.Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib[J]. Clin Cancer Res,2011,17(13):4504-4512. [23] Godoy MC, Naidich DP, Marchiori E, et al.Basic principles and postprocessing techniques of dual-energy CT: illustrated by selected congenital abnormalities of the thorax[J]. J Thorac Imaging,2009,24(2):152-159. [24] Toepker M, Moritz T, Krauss B, et al.Virtual non-contrast in second-generation, dual-energy computed tomography: reliability of attenuation values[J]. Eur J Radiol,2012,81(3):e398-e405. |